Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchZincZinc (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis       

Zinc use is associated with improved outcomes in COVID-19: results from the CRUSH-COVID registry

Mayberry et al., Critical Care Medicine, doi:10.1097/01.ccm.0000807104.82650.d6
Dec 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 53% Improvement Relative Risk Ventilation 64% ICU admission 60% Death/ventilation/ICU 58% primary Progression to ARDS 85% Zinc for COVID-19  Mayberry et al.  EARLY TREATMENT Is early treatment with zinc beneficial for COVID-19? Retrospective 2,028 patients in the USA (March 2020 - April 2021) Lower mortality (p<0.0001) and ventilation (p<0.0001) c19early.org Mayberry et al., Critical Care Medicine, Dec 2021 Favorszinc Favorscontrol 0 0.5 1 1.5 2+
Zinc for COVID-19
2nd treatment shown to reduce risk in July 2020, now with p = 0.00000032 from 46 studies, recognized in 17 countries.
No treatment is 100% effective. Protocols combine treatments.
5,100+ studies for 112 treatments. c19early.org
Retrospective 2,028 COVID patients in the USA, showing significantly lower mortality, ventilation, ICU admission, and progression to ARDS with zinc use, defined as at least one dose from one week prior to admission to 48 hours after admission.
risk of death, 53.5% lower, OR 0.47, p < 0.001, treatment 938, control 1,090, adjusted per study, multivariable, RR approximated with OR.
risk of mechanical ventilation, 64.2% lower, OR 0.36, p < 0.001, treatment 938, control 1,090, adjusted per study, multivariable, RR approximated with OR.
risk of ICU admission, 60.0% lower, OR 0.40, p < 0.001, treatment 938, control 1,090, adjusted per study, multivariable, RR approximated with OR.
death/ventilation/ICU, 57.8% lower, OR 0.42, p < 0.001, treatment 938, control 1,090, adjusted per study, multivariable, primary outcome, RR approximated with OR.
progression to ARDS, 85.4% lower, OR 0.15, p < 0.001, treatment 938, control 1,090, adjusted per study, multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Mayberry et al., 16 Dec 2021, retrospective, USA, peer-reviewed, 14 authors, study period March 2020 - April 2021.
This PaperZincAll
{ 'indexed': { 'date-parts': [[2021, 12, 22]], 'date-time': '2021-12-22T06:50:45Z', 'timestamp': 1640155845018}, 'reference-count': 0, 'publisher': 'Ovid Technologies (Wolters Kluwer Health)', 'issue': '1', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'short-container-title': [], 'published-print': {'date-parts': [[2022, 1]]}, 'DOI': '10.1097/01.ccm.0000807104.82650.d6', 'type': 'journal-article', 'created': { 'date-parts': [[2021, 12, 16]], 'date-time': '2021-12-16T20:06:47Z', 'timestamp': 1639685207000}, 'page': '81-81', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': [ '195: ZINC USE IS ASSOCIATED WITH IMPROVED OUTCOMES IN COVID-19: RESULTS FROM THE CRUSH-COVID ' 'REGISTRY'], 'prefix': '10.1097', 'volume': '50', 'author': [ {'given': 'Miles', 'family': 'Mayberry', 'sequence': 'first', 'affiliation': []}, {'given': 'Jonathan', 'family': 'Chow', 'sequence': 'additional', 'affiliation': []}, {'given': 'Paul', 'family': 'Park', 'sequence': 'additional', 'affiliation': []}, {'given': 'Lynnette', 'family': 'Harris', 'sequence': 'additional', 'affiliation': []}, {'given': 'Amit', 'family': 'Saha', 'sequence': 'additional', 'affiliation': []}, {'given': 'Andrea', 'family': 'Levine', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nathan', 'family': 'Smischney', 'sequence': 'additional', 'affiliation': []}, {'given': 'Patrick', 'family': 'Wieruszewski', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nikhil', 'family': 'Meena', 'sequence': 'additional', 'affiliation': []}, {'given': 'David', 'family': 'Yamane', 'sequence': 'additional', 'affiliation': []}, {'given': 'Amanda', 'family': 'Jackson', 'sequence': 'additional', 'affiliation': []}, {'given': 'Shravan', 'family': 'Kethireddy', 'sequence': 'additional', 'affiliation': []}, {'given': 'Matthew', 'family': 'Wiepking', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ashish', 'family': 'Khanna', 'sequence': 'additional', 'affiliation': []}], 'member': '276', 'published-online': {'date-parts': [[2021, 12, 16]]}, 'container-title': ['Critical Care Medicine'], 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://journals.lww.com/10.1097/01.ccm.0000807104.82650.d6', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 12, 21]], 'date-time': '2021-12-21T12:16:45Z', 'timestamp': 1640089005000}, 'score': 1, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 12, 16]]}, 'references-count': 0, 'journal-issue': {'issue': '1', 'published-print': {'date-parts': [[2022]]}}, 'URL': 'http://dx.doi.org/10.1097/01.ccm.0000807104.82650.d6', 'relation': {}, 'ISSN': ['0090-3493'], 'issn-type': [{'value': '0090-3493', 'type': 'print'}], 'subject': ['Critical Care and Intensive Care Medicine'], 'published': {'date-parts': [[2021, 12, 16]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit